Le Lézard
Classified in: Health
Subjects: PDT, FDA

HemoCue Announces FDA 510(k) Clearance and U.S. Launch of Its Latest Point-of-Care Hemoglobin Test, the HemoCue® Hb 801 System

BREA, Calif., Feb. 20, 2019 /PRNewswire/ -- HemoCue, the pioneer and global leader of point-of-care hemoglobin (Hb) testing (with HemoCue AB global headquarters in Ängelholm, Sweden), announced it received Food and Drug Administration (FDA) 510(k) clearance1 of the HemoCue® Hb 801 System, its newest test that enables healthcare providers to assess patients' hemoglobin levels while present in their clinics.  Subsequently, HemoCue has announced immediate commercial availability of the HemoCue® Hb 801 System to physician lab offices across the United States.

"HemoCue is a pioneer in point-of-care testing," said Christophe Duret, president of HemoCue AB. "Our tests make it easy for clinicians to get a lab-quality result while the patient is present, which allows for more engagement in the overall healthcare process."

Hemoglobin testing helps clinicians to detect anemia, a condition in which the body lacks enough healthy red blood cells, or hemoglobin.  Anemia, in most cases, is very treatable. 

The HemoCue® Hb 801 System quantitatively measures hemoglobin in capillary or venous whole blood, and is for professional in vitro diagnostic use only.  The HemoCue® Hb 801 System is intended to be used to determine the hemoglobin concentration for adults, adolescents, children, and infants above 1 month old.  The HemoCue® Hb 801 System consists of an analyzer together with microcuvettes, and is CLIA-waived.  The HemoCue® Hb 801 System seamlessly integrates into your daily clinic operation with such advancements as:

"With more than 35 years in point-of-care testing, we understand the everyday challenges to ensure a smooth-running clinic as critical to patient care," said Chris Mueller, interim general manager of HemoCue America.  "The advancements of our HemoCue® Hb 801 System, combined with our comprehensive service offering, enable point-of-care hemoglobin testing to fit seamlessly into a clinic's daily workflow." 

HemoCue owns and operates all aspects of a customer's experience, providing direct support from one source. This level of support provides a best-in-class comprehensive offering, including:

About HemoCue

HemoCue is a global leader in point-of-care hemoglobin testing. In 1982, HemoCue AB, based in Ängelholm, Sweden, introduced the first system making accurate hemoglobin testing possible in near-patient settings. Since then, more than 400,000 HemoCue systems have been sold worldwide. The company also offers point-of-care tests for glucose, urine albumin, HbA1c, total and differential white blood cell count. HemoCue subsidiaries, franchises, and third-party distributors supply HemoCue products in more than 130 countries worldwide. HemoCue has been part of the Danaher Corporation's diagnostic platform since April 2013.


1 K181751; FDA cleared on February 1, 2019

*Consult individual state and/or organization regulations


SOURCE HemoCue America

These press releases may also interest you

at 09:10
PharmaCyte Biotech, Inc. , a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that its quarterly shareholder update will be...

at 09:10
Global Next-Generation Visualization and Navigation Systems Market to Reach $4.34 Billion by 2029 Read the full report: https://www.reportlinker.com/p05832142/?utm_source=PRN Key Questions Answered in this Report:? How is the role of next-generation...

at 09:09
FCB was named "Network of the Year" by the 2019 Clio Health Awards today, while AREA 23 was named "Agency of the Year" for the third consecutive year. FCB took home a total of 26 accolades, including 22 for FCB Health Network agencies AREA 23, FCB...

at 09:08
MediRevv, a national revenue cycle management company and Providence, a national not-for-profit Catholic health system announced today that they've expanded their end-to-end revenue cycle model to include Providence Medical Institute (PMI) and...

at 09:05
SCIEX, a global leader in life science analytical technologies, announced that it joined the Ready-to-Run Partner Program at Genedata, a leading provider of advanced software solutions for biopharmaceutical R&D. This will help SCIEX and Genedata...

at 09:05
Partnership With Native Americans (PWNA), a nonprofit serving immediate needs and supporting long-term solutions for Native Americans living in reservation communities, announced today the appointment of Joshua Arce as their new president and chief...

News published on 20 february 2019 at 10:00 and distributed by: